QualityStocks would like to highlight Advaxis, Inc. (http://www.qualitystocks.net/stocks1.html">OTCBB: ADXS), a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein that is designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself.
In the company’s news,
Advaxis is developing a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to the bacteria to the cancer itself.
The company’s approach has been determined to outsmart tumor protection reactions that foil other treatments, while also generating a long-term immune system “memory” that is able to hunt down cancer cells throughout the body beyond the initially targeted antigens. And, being an immunotherapy, it does it all without the poisons and associated side effects of traditional chemotherapy treatments.
Advaxis immunotherapies are designed to stimulate many complementary immune mechanisms of action, including:
• Strong innate immune effects
• Strong adaptive immune effects
• Reduction of both Tregs and MDSCs in tumors but not in other tissues or systemically
• Memory generation that is not impaired by antibiotics administered immediately after dosing
• Chemotaxis and extravasation of activated immune cells
• Upregulation of tumor chemokines and chemokines receptors
• Epitope and antigen spreading
• A predominantly cellular immune response with little antibody formation
Over 15 distinct constructs are in various stages of development, either developed directly by Advaxis or through strategic collaborations with recognized centers of excellence, such as the National Cancer Institute. The company’s first construct, ADXS-HPV, is being evaluated in 4 Phase 2 clinical trials for HPV associated diseases (CIN 2/3, cervical cancer, and head & neck cancer). In addition, Advaxis has developed immunotherapies for prostate cancer and HER2 expressing cancers (such as breast, gastric, bladder, brain, pancreatic, ovarian cancer, and canine osteosarcoma).
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.